IFRX

Jena, Germany, Nov. 06, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the peer-reviewed publication of first-in-human Phase 1 clinical data for izicopan, formerly known as INF904, the Company's orally administered, next-generation small molecule inhibitor of the C5a receptor (C5aR1). The publication reports results from the Company's single ascending dose (SAD) and multiple ascending dose (MAD) study in 86 healthy participants. The positive results of these studies were previously announced.

InflaRx N.V. ( IFRX ) Analyst/Investor Day November 3, 2026 8:00 AM EST Company Participants Jan Medina - Head of Investor Relations & VP Niels Riedemann - Co-Founder, CEO & Executive Director Thomas Taapken - Chief Financial Officer Conference Call Participants Jörg Köhl Peter Merkel Yatin Suneja - Guggenheim Securities, LLC, Research Division Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Samuel Slutsky - LifeSci Capital, LLC, Research Division Mazahir Alimohamed - Oppenheimer & Co. Inc., Research Division Joseph Stringer - Needham & Company, LLC, Research Division Ryan Deschner - Raymond James & Associates, Inc., Research Division Dev Prasad - Lucid Capital Markets, LLC, Research Division Presentation Jan Medina Head of Investor Relations & VP Ladies and gentlemen, good morning, and thank you for standing by, and thank you for joining the InflaRx Capital Markets event to discuss the evolving treatment landscape and unmet need in AAV as well as our development strategy for izicopan in AAV and other renal indications.

InflaRx NASDAQ: IFRX outlined plans to advance its oral C5a receptor antagonist izicopan in ANCA-associated vasculitis (AAV), with an initial focus on patients with kidney involvement and a parallel study intended to evaluate corticosteroid reduction.

With a goal of providing multiple data sets demonstrating differentiated efficacy and safety in multiple ANCA-associated vasculitis (AAV) settings, InflaRx intends to begin two Phase 2 trials in 2027, with first data readout anticipated in 2028 Phase 2 AAV izicopan program expected to include a placebo-controlled randomized study in patients with renal involvement with site initiation in early 2027, as well as an open-label “all-comers” study to demonstrate the ability to replace corticosteroids Initial data from an investigator-initiated open-label pilot study in atypical hemolytic uremic syndrome (aHUS) anticipated in the second half of 2027 InflaRx planning pilot study in IgA nephropathy (IgAN) to be initiated in 2027, with expected early data readout in 2028 InflaRx announces Advisory Board comprised of leading international experts in vasculitis, nephrology and immune-mediated renal disease InflaRx proprietary research indicates izicopan's product profile supports the potential for significant AAV market expansion, with an estimated peak sales potential in the range of $1.5 - 2.0 billion BDB-001, a vilobelimab cell line-produced antibody targeting C5a and being evaluated by InflaRx's collaborator, Staidson BioPharmaceuticals Co., Ltd. (Staidson), is currently in a Phase 3 trial in AAV in China, with data anticipated in 2H 2028 Cash, cash equivalents and marketable securities totaled €153.3 million on September 30, 2026, expected to fund ongoing operations and clinical development through 2029 Jena, Germany, Nov. 03, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V.

Jena, Germany, Oct. 27, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its events calendar for November.

Jena, Germany, Oct. 22, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the presentation of new pre-clinical data on izicopan in renal disease models at the American Society of Nephrology's Kidney Week 2026, taking place in Denver, Colorado, October 21 - 25. The in vivo and in vitro data demonstrated that izicopan robustly inhibited C5aR-mediated inflammatory responses and provided renal protection, supporting its potential as a therapeutic candidate for complement-driven kidney diseases.

Jena, Germany, Oct. 02, 2026 (GLOBE NEWSWIRE) --  InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company has been selected for a late-breaking poster session at the American Society of Nephrology's Kidney Week 2026, taking place in Denver, Colorado, USA, October 21 - 25.

Jena, Germany, Oct. 01, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the appointment of Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development, effective October 1, 2026.

Event to be hosted on November 3, 2026 at 8:00 AM EST Featured speakers will include Peter A. Merkel, MD, MPH and Prof.

Jena, Germany, Aug. 20, 2026 (GLOBE NEWSWIRE) --  InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in two investor conferences in September 2026. Details are as follows: